Top

Published in:

01-12-2012 | Mediators, Mechanisms, and Pathways in Tissue Injury (B Rothermel, Section Editor)

Circulating miRNAs: Reflecting or Affecting Cardiovascular Disease?

Authors: Vanessa P. M. van Empel, Leon J. De Windt, Paula A. da Costa Martins

Published in: Current Hypertension Reports | Issue 6/2012

Abstract

MicroRNAs are a class of small, noncoding RNAs encoded by the metazoan genome that regulate protein expression. A collection of studies point to vital roles for microRNAs in the onset and development of cardiovascular diseases. So far, microRNAs have been considered as important intracellular mediators in maintaining proper cardiac function and hemostasis, and have been proposed as potential therapeutic targets in cardiovascular disease. The recent discovery that microRNAs circulate in a stable form in many body fluids, including blood, suggests that circulating microRNAs can serve as a new generation of biomarkers for cardiovascular diseases. In this review, we summarize the findings of studies focusing on circulating microRNAs present in human blood cells or plasma/serum, where they potentially could serve as diagnostic or prognostic markers for a variety of cardiovascular pathologies, including acute myocardial infarction, heart failure, coronary artery disease, stroke, diabetes and hypertension. The significance and limitations of microRNAs as the new biomarker generation for cardiovascular disease are also discussed.

van Rooij E, Sutherland LB, Thatcher JE, DiMaio JM, Naseem RH, Marshall WS, Hill JA, Olson EN. Dysregulation of micrornas after myocardial infarction reveals a role of mir-29 in cardiac fibrosis. Proc Natl Acad Sci U S A. 2008;105:13027–32.PubMedCrossRef

da Costa Martins PA, Salic K, Gladka MM, Armand AS, Leptidis S, el Azzouzi H, Hansen A, Coenen-de Roo CJ, Bierhuizen MF, van der Nagel R, van Kuik J, de Weger R, de Bruin A, Condorelli G, Arbones ML, Eschenhagen T, De Windt LJ. Microrna-199b targets the nuclear kinase dyrk1a in an auto-amplification loop promoting calcineurin/nfat signalling. Nat Cell Biol. 2010;12:1220–7.PubMedCrossRef

Sayed D, Hong C, Chen IY, Lypowy J, Abdellatif M. Micrornas play an essential role in the development of cardiac hypertrophy. Circ Res. 2007;100:416–24.PubMedCrossRef

Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, Galuppo P, Just S, Rottbauer W, Frantz S, Castoldi M, Soutschek J, Koteliansky V, Rosenwald A, Basson MA, Licht JD, Pena JT, Rouhanifard SH, Muckenthaler MU, Tuschl T, Martin GR, Bauersachs J, Engelhardt S. Microrna-21 contributes to myocardial disease by stimulating map kinase signalling in fibroblasts. Nature. 2008;456:980–4.PubMedCrossRef

Bonauer A, Carmona G, Iwasaki M, Mione M, Koyanagi M, Fischer A, Burchfield J, Fox H, Doebele C, Ohtani K, Chavakis E, Potente M, Tjwa M, Urbich C, Zeiher AM, Dimmeler S. Microrna-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science. 2009;324:1710–3.PubMedCrossRef

Suarez Y, Sessa WC. Micrornas as novel regulators of angiogenesis. Circ Res. 2009;104:442–54.PubMedCrossRef

Thum T, Galuppo P, Wolf C, Fiedler J, Kneitz S, van Laake LW, Doevendans PA, Mummery CL, Borlak J, Haverich A, Gross C, Engelhardt S, Ertl G, Bauersachs J. Micrornas in the human heart: A clue to fetal gene reprogramming in heart failure. Circulation. 2007;116:258–67.PubMedCrossRef

van Rooij E, Sutherland LB, Liu N, Williams AH, McAnally J, Gerard RD, Richardson JA, Olson EN. A signature pattern of stress-responsive micrornas that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci U S A. 2006;103:18255–60.PubMedCrossRef

Chim SS, Shing TK, Hung EC, Leung TY, Lau TK, Chiu RW, Lo YM. Detection and characterization of placental micrornas in maternal plasma. Clin Chem. 2008;54:482–90.PubMedCrossRef

10.

Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Pezzella F, Boultwood J, Wainscoat JS, Hatton CS, Harris AL. Detection of elevated levels of tumour-associated micrornas in serum of patients with diffuse large b-cell lymphoma. Br J Haematol. 2008;141:672–5.PubMedCrossRef

11.

Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, Li Q, Li X, Wang W, Wang J, Jiang X, Xiang Y, Xu C, Zheng P, Zhang J, Li R, Zhang H, Shang X, Gong T, Ning G, Zen K, Zhang CY. Characterization of micrornas in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;18:997–1006.PubMedCrossRef

12.

Tsui NB, Ng EK, Lo YM. Stability of endogenous and added rna in blood specimens, serum, and plasma. Clin Chem. 2002;48:1647–53.PubMed

13.

• Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, Mitchell PS, Bennett CF, Pogosova-Agadjanyan EL, Stirewalt DL, Tait JF, Tewari M. Argonaute2 complexes carry a population of circulating micrornas independent of vesicles in human plasma. Proc Natl Acad Sci U S A. 2011;108:5003–5008. This study demonstrates that most circulating miRNAs are protein-, mainly Ago2-, bound. PubMedCrossRef

14.

• Hunter MP, Ismail N, Zhang X, Aguda BD, Lee EJ, Yu L, Xiao T, Schafer J, Lee ML, Schmittgen TD, Nana-Sinkam SP, Jarjoura D, Marsh CB. Detection of microrna expression in human peripheral blood microvesicles. PLoS One. 2008;3:e3694. This work shows that stable miRNAs are carried by microvesicles in the circulation. PubMedCrossRef

15.

• Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mrnas and micrornas is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9:654–659. This study demonstrates that exosomes contain stable mRNAs and miRNAs in the circulation and can mediate transporte between cells. PubMedCrossRef

16.

Wang K, Zhang S, Weber J, Baxter D, Galas DJ. Export of micrornas and microrna-protective protein by mammalian cells. Nucleic Acids Res. 2010;38:7248–59.PubMedCrossRef

17.

Suleymanoglu E. Phospholipid-nucleic acid recognition: Developing an immobilized liposome chromatography for DNA separation and analysis. PDA J Pharm Sci Technol. 2006;60:232–9.PubMed

18.

Janas T, Yarus M. Specific rna binding to ordered phospholipid bilayers. Nucleic Acids Res. 2006;34:2128–36.PubMedCrossRef

19.

Manavbasi Y, Suleymanoglu E. Nucleic acid-phospholipid recognition: Fourier transform infrared spectrometric characterization of ternary phospholipid-inorganic cation-DNA complex and its relevance to chemicopharmaceutical design of nanometric liposome based gene delivery formulations. Arch Pharm Res. 2007;30:1027–40.PubMedCrossRef

20.

Lou B, Liao XL, Wu MP, Cheng PF, Yin CY, Fei Z. High-density lipoprotein as a potential carrier for delivery of a lipophilic antitumoral drug into hepatoma cells. World J Gastroenterol. 2005;11:954–9.PubMed

21.

• Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT. Micrornas are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol. 2011;13:423–433. Here, HLD is identified as a transport system for miRNAs in circulation that enables intracellular communication. PubMedCrossRef

22.

Skog J, Wurdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M, Curry Jr WT, Carter BS, Krichevsky AM, Breakefield XO. Glioblastoma microvesicles transport rna and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008;10:1470–6.PubMedCrossRef

23.

Mause SF, Weber C. Microparticles: Protagonists of a novel communication network for intercellular information exchange. Circ Res. 2010;107:1047–57.PubMedCrossRef

24.

Lee YS, Pressman S, Andress AP, Kim K, White JL, Cassidy JJ, Li X, Lubell K, Lim do H, Cho IS, Nakahara K, Preall JB, Bellare P, Sontheimer EJ, Carthew RW. Silencing by small rnas is linked to endosomal trafficking. Nat Cell Biol. 2009;11:1150–6.PubMedCrossRef

25.

•• Zernecke A, Bidzhekov K, Noels H, Shagdarsuren E, Gan L, Denecke B, Hristov M, Koppel T, Jahantigh MN, Lutgens E, Wang S, Olson EN, Schober A, Weber C. Delivery of microrna-126 by apoptotic bodies induces cxcl12-dependent vascular protection. Sci Signal. 2009;2:81. This study shows that apoptotic bodies generated during atherosclerosis are able to convey paracrine signals to target vascular cells triggering their response. Furthermore, miR-126 was shown to be transported in circulation via apoptotic bodies to recipient cells. PubMedCrossRef

26.

Ohshima K, Inoue K, Fujiwara A, Hatakeyama K, Kanto K, Watanabe Y, Muramatsu K, Fukuda Y, Ogura S, Yamaguchi K, Mochizuki T. Let-7 microrna family is selectively secreted into the extracellular environment via exosomes in a metastatic gastric cancer cell line. PLoS One. 2010;5:e13247.PubMedCrossRef

27.

Zhang Y, Liu D, Chen X, Li J, Li L, Bian Z, Sun F, Lu J, Yin Y, Cai X, Sun Q, Wang K, Ba Y, Wang Q, Wang D, Yang J, Liu P, Xu T, Yan Q, Zhang J, Zen K, Zhang CY. Secreted monocytic mir-150 enhances targeted endothelial cell migration. Mol Cell. 2010;39:133–44.PubMedCrossRef

28.

Alpert JS, Thygesen K, Jaffe A, White HD. The universal definition of myocardial infarction: A consensus document: Ischaemic heart disease. Heart. 2008;94:1335–41.PubMedCrossRef

29.

Jaffe AS, Ravkilde J, Roberts R, Naslund U, Apple FS, Galvani M, Katus H. It’s time for a change to a troponin standard. Circulation. 2000;102:1216–20.PubMedCrossRef

30.

Shand JA, Howe A. Ckmb and troponin i levels post coronary artery bypass surgery show a graded association with mortality. Biomark Med. 2011;5:375.

31.

Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernandez-Aviles F, Fox KA, Hasdai D, Ohman EM, Wallentin L, Wijns W. Guidelines for the diagnosis and treatment of non-st-segment elevation acute coronary syndromes. Eur Heart J. 2007;28:1598–660.PubMedCrossRef

32.

Lauer B, Niederau C, Kuhl U, Schannwell M, Pauschinger M, Strauer BE, Schultheiss HP. Cardiac troponin t in patients with clinically suspected myocarditis. J Am Coll Cardiol. 1997;30:1354–9.PubMedCrossRef

33.

Agewall S, Giannitsis E, Jernberg T, Katus H. Troponin elevation in coronary vs. Non-coronary disease. Eur Heart J. 2011;32:404–11.PubMedCrossRef

34.

van Rooij E, Sutherland LB, Qi X, Richardson JA, Hill J, Olson EN. Control of stress-dependent cardiac growth and gene expression by a microrna. Science. 2007;316:575–9.PubMedCrossRef

35.

•• Corsten MF, Dennert R, Jochems S, Kuznetsova T, Devaux Y, Hofstra L, Wagner DR, Staessen JA, Heymans S, Schroen B. Circulating microrna-208b and microrna-499 reflect myocardial damage in cardiovascular disease. Circ Cardiovasc Genet. 2010;3:499–506. This study shows miR-208b and miR-499 to be the most upregulated miRNAs in circulation in 32 AMI patients. There is a correlation between both miRNA levels and TnT levels in circulation. PubMedCrossRef

36.

•• D’Alessandra Y, Devanna P, Limana F, Straino S, Di Carlo A, Brambilla PG, Rubino M, Carena MC, Spazzafumo L, De Simone M, Micheli B, Biglioli P, Achilli F, Martelli F, Maggiolini S, Marenzi G, Pompilio G, Capogrossi MC. Circulating micrornas are new and sensitive biomarkers of myocardial infarction. Eur Heart J. 2010;31:2765–2773. This work indicates that miR-1, miR-133a, miR-133b and miR-499 are the most abundant circulating miRNAs in 33 STEMI patients. It also shows that circulating miR-208a is increased in a mouse model of MI. PubMedCrossRef

37.

Fukushima Y, Nakanishi M, Nonogi H, Goto Y, Iwai N. Assessment of plasma mirnas in congestive heart failure. Circ J. 2011;75:336–40.PubMedCrossRef

38.

Adachi T, Nakanishi M, Otsuka Y, Nishimura K, Hirokawa G, Goto Y, Nonogi H, Iwai N. Plasma microrna 499 as a biomarker of acute myocardial infarction. Clin Chem. 2010;56:1183–5.PubMedCrossRef

39.

Fichtlscherer S, De Rosa S, Fox H, Schwietz T, Fischer A, Liebetrau C, Weber M, Hamm CW, Roxe T, Muller-Ardogan M, Bonauer A, Zeiher AM, Dimmeler S. Circulating micrornas in patients with coronary artery disease. Circ Res. 2010;107:677–84.PubMedCrossRef

40.

•• Cheng Y, Tan N, Yang J, Liu X, Cao X, He P, Dong X, Qin S, Zhang C. A translational study of circulating cell-free microrna-1 in acute myocardial infarction. Clin Sci (Lond). 2010;119:87–95. This study shows increased levels of circulating miR-1 in 31 AMI patients, and in a rat model of MI. Furthermore, miR-1 levels correlate with CK-MB levels in AMI patients, with infarct size in the animal model and with the degree of cell damage. CrossRef

41.

Callis TE, Pandya K, Seok HY, Tang RH, Tatsuguchi M, Huang ZP, Chen JF, Deng Z, Gunn B, Shumate J, Willis MS, Selzman CH, Wang DZ. Microrna-208a is a regulator of cardiac hypertrophy and conduction in mice. J Clin Invest. 2009;119:2772–86.PubMedCrossRef

42.

Thompson WR, Nadal-Ginard B, Mahdavi V. A myod1-independent muscle-specific enhancer controls the expression of the beta-myosin heavy chain gene in skeletal and cardiac muscle cells. J Biol Chem. 1991;266:22678–88.PubMed

43.

•• Ai J, Zhang R, Li Y, Pu J, Lu Y, Jiao J, Li K, Yu B, Li Z, Wang R, Wang L, Li Q, Wang N, Shan H, Yang B. Circulating microrna-1 as a potential novel biomarker for acute myocardial infarction. Biochem Biophys Res Commun. 2010;391:73–77. This work shows increased circulating levels of miR-1 in 93 AMI patients, which correlate with QRS widening. Furthermore, this was the first study identifying specific circulating miRNA signatures in CAD patients. PubMedCrossRef

44.

•• Meder B, Keller A, Vogel B, Haas J, Sedaghat-Hamedani F, Kayvanpour E, Just S, Borries A, Rudloff J, Leidinger P, Meese E, Katus HA, Rottbauer W. Microrna signatures in total peripheral blood as novel biomarkers for acute myocardial infarction. Basic Res Cardiol. 2011;106:13–23. This study suggests a miRNA signature (multimarker) as a novel biomarker of MI. PubMedCrossRef

45.

•• Gidlof O, Andersson P, van der Pals J, Gotberg M, Erlinge D. Cardiospecific microrna plasma levels correlate with troponin and cardiac function in patients with st elevation myocardial infarction, are selectively dependent on renal elimination, and can be detected in urine samples. Cardiology. 2011;118:217–226. This study shows an increase in circulating miR-1, miR-133a, miR-208b and miR-499 levels in 25 STEMI patients, and in a pig model of MI. Levels of circulating miR-208b correlate with TnT levels in circulation after MI. PubMedCrossRef

46.

•• Zampetaki A, Kiechl S, Drozdov I, Willeit P, Mayr U, Prokopi M, Mayr A, Weger S, Oberhollenzer F, Bonora E, Shah A, Willeit J, Mayr M. Plasma microrna profiling reveals loss of endothelial mir-126 and other micrornas in type 2 diabetes. Circ Res. 2010;107:810–817. This study reveals a plasma signature for type 2 diabetes, including decreased levels of circulating miR-126. PubMedCrossRef

47.

Zampetaki A, Willeit P, Tilling L, Drozdov I, Prokopi M, Renard JM, Mayr A, Weger S, Schett G, Shah A, Boulanger CM, Willeit J, Chowienczyk PJ, Kiechl S, Mayr M. Prospective study on circulating micrornas and risk of myocardial infarction. J Am Coll Cardiol. 2012;60:290–9.PubMedCrossRef

48.

• Tijsen AJ, Creemers EE, Moerland PD, de Windt LJ, van der Wal AC, Kok WE, Pinto YM. Mir423-5p as a circulating biomarker for heart failure. Circ Res. 2010;106:1035–1039. This study identified a specific circulating miRNA signature in patients with HF. MiR-423-5p is one of the strongest elevated miRNAs, strongly correlating with the clinical diagnosis of HF. PubMedCrossRef

49.

• Laterza OF, Lim L, Garrett-Engele PW, Vlasakova K, Muniappa N, Tanaka WK, Johnson JM, Sina JF, Fare TL, Sistare FD, Glaab WE. Plasma micrornas as sensitive and specific biomarkers of tissue injury. Clin Chem. 2009;55:1977–1983. This study suggests tissue-specific miRNAs as sensitive biomarkers of tissue injury. Circulating miR-124 levels, a brain-specific miRNA, are increased upon cerebral ischemia. PubMedCrossRef

50.

Jeyaseelan K, Lim KY, Armugam A. Microrna expression in the blood and brain of rats subjected to transient focal ischemia by middle cerebral artery occlusion. Stroke. 2008;39:959–66.PubMedCrossRef

51.

Voellenkle C, van Rooij J, Cappuzzello C, Greco S, Arcelli D, Di Vito L, Melillo G, Rigolini R, Costa E, Crea F, Capogrossi MC, Napolitano M, Martelli F. Microrna signatures in peripheral blood mononuclear cells of chronic heart failure patients. Physiol Genomics. 2010;42:420–6.PubMedCrossRef

52.

Rosamond WD, Folsom AR, Chambless LE, Wang CH, McGovern PG, Howard G, Copper LS, Shahar E. Stroke incidence and survival among middle-aged adults: 9-year follow-up of the atherosclerosis risk in communities (aric) cohort. Stroke. 1999;30:736–43.PubMedCrossRef

53.

Tan KS, Armugam A, Sepramaniam S, Lim KY, Setyowati KD, Wang CW, Jeyaseelan K. Expression profile of micrornas in young stroke patients. PLoS One. 2009;4:e7689.PubMedCrossRef

54.

Saenger AK, Christenson RH. Stroke biomarkers: Progress and challenges for diagnosis, prognosis, differentiation, and treatment. Clin Chem. 2010;56:21–33.PubMedCrossRef

55.

Kong L, Zhu J, Han W, Jiang X, Xu M, Zhao Y, Dong Q, Pang Z, Guan Q, Gao L, Zhao J, Zhao L. Significance of serum micrornas in pre-diabetes and newly diagnosed type 2 diabetes: A clinical study. Acta Diabetol. 2011;48:61–9.PubMedCrossRef

56.

Liu DZ, Tian Y, Ander BP, Xu H, Stamova BS, Zhan X, Turner RJ, Jickling G, Sharp FR. Brain and blood microrna expression profiling of ischemic stroke, intracerebral hemorrhage, and kainate seizures. J Cereb Blood Flow Metab. 2010;30:92–101.PubMedCrossRef

57.

Zeng L, Liu J, Wang Y, Wang L, Weng S, Tang Y, Zheng C, Cheng Q, Chen S, Yang GY. Microrna-210 as a novel blood biomarker in acute cerebral ischemia. Front Biosci (Elite Ed). 2011;3:1265–72.

58.

Fasanaro P, Greco S, Ivan M, Capogrossi MC, Martelli F. Microrna: Emerging therapeutic targets in acute ischemic diseases. Pharmacol Ther. 2010;125:92–104.PubMedCrossRef

59.

Devlin C, Greco S, Martelli F, Ivan M. Mir-210: More than a silent player in hypoxia. IUBMB Life. 2011;63:94–100.PubMed

60.

Fasanaro P, D’Alessandra Y, Di Stefano V, Melchionna R, Romani S, Pompilio G, Capogrossi MC, Martelli F. Microrna-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand ephrin-a3. J Biol Chem. 2008;283:15878–83.PubMedCrossRef

61.

Gan CS, Wang CW, Tan KS. Circulatory microrna-145 expression is increased in cerebral ischemia. Genet Mol Res. 2012;11:147–52.PubMedCrossRef

62.

Cordes KR, Sheehy NT, White MP, Berry EC, Morton SU, Muth AN, Lee TH, Miano JM, Ivey KN, Srivastava D. Mir-145 and mir-143 regulate smooth muscle cell fate and plasticity. Nature. 2009;460:705–10.PubMed

63.

•• Widera C, Gupta SK, Lorenzen JM, Bang C, Bauersachs J, Bethmann K, Kempf T, Wollert KC, Thum T. Diagnostic and prognostic impact of six circulating micrornas in acute coronary syndrome. J Mol Cell Cardiol. 2011;51:872–875. This study shows elevated levels of circulating miR-1, miR-133a and miR-208b in 196 STEMI patients, which correlate with circulating levels of high-sensitive TnT. PubMedCrossRef

64.

Long X, Bell RD, Gerthoffer WT, Zlokovic BV, Miano JM. Myocardin is sufficient for a smooth muscle-like contractile phenotype. Arterioscler Thromb Vasc Biol. 2008;28:1505–10.PubMedCrossRef

65.

Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011;473:317–25.PubMedCrossRef

66.

•• Hoekstra M, van der Lans CA, Halvorsen B, Gullestad L, Kuiper J, Aukrust P, van Berkel TJ, Biessen EA. The peripheral blood mononuclear cell microrna signature of coronary artery disease. Biochem Biophys Res Commun. 2010;394:792–797. This study shows that miRNAs can be used as sensitive biomarkers of CAD. Unstable angina pectoris patients can be discriminated from stable patients based on increased levels of circulating miR-134, miR-198 and miR-370. PubMedCrossRef

67.

Urbich C, Dimmeler S. Endothelial progenitor cells: Characterization and role in vascular biology. Circ Res. 2004;95:343–53.PubMedCrossRef

68.

• Li T, Cao H, Zhuang J, Wan J, Guan M, Yu B, Li X, Zhang W. Identification of mir-130a, mir-27b and mir-210 as serum biomarkers for atherosclerosis obliterans. Clin Chim Acta. 2011;412:66–70. This is the first study showing decreased levels of miR-181a in monocytes of obese patients and monocytic miRNAs as biomarkers of CAD and the metabolic syndrome. PubMedCrossRef

69.

Hulsmans M, Sinnaeve P, Van der Schueren B, Mathieu C, Janssens S, Holvoet P. Decreased mir-181a expression in monocytes of obese patients is associated with the occurrence of metabolic syndrome and coronary artery disease. J Clin Endocrinol Metab. 2012;97:E1213–8.PubMedCrossRef

70.

Frankel DS, Meigs JB, Massaro JM, Wilson PW, O’Donnell CJ, D’Agostino RB, Tofler GH. Von willebrand factor, type 2 diabetes mellitus, and risk of cardiovascular disease: The framingham offspring study. Circulation. 2008;118:2533–9.PubMedCrossRef

71.

Nathan DM. Long-term complications of diabetes mellitus. N Engl J Med. 1993;328:1676–85.PubMedCrossRef

72.

Herder C, Karakas M, Koenig W. Biomarkers for the prediction of type 2 diabetes and cardiovascular disease. Clin Pharmacol Ther. 2011;90:52–66.PubMedCrossRef

73.

Wang S, Aurora AB, Johnson BA, Qi X, McAnally J, Hill JA, Richardson JA, Bassel-Duby R, Olson EN. The endothelial-specific microrna mir-126 governs vascular integrity and angiogenesis. Dev Cell. 2008;15:261–71.PubMedCrossRef

74.

Meng S, Cao JT, Zhang B, Zhou Q, Shen CX, Wang CQ. Downregulation of microrna-126 in endothelial progenitor cells from diabetes patients, impairs their functional properties, via target gene spred-1. J Mol Cell Cardiol. 2012;53:64–72.PubMedCrossRef

75.

Pandey AK, Agarwal P, Kaur K, Datta M. Micrornas in diabetes: Tiny players in big disease. Cell Physiol Biochem. 2009;23:221–32.PubMedCrossRef

76.

•• Caporali A, Meloni M, Vollenkle C, Bonci D, Sala-Newby GB, Addis R, Spinetti G, Losa S, Masson R, Baker AH, Agami R, le Sage C, Condorelli G, Madeddu P, Martelli F, Emanueli C. Deregulation of microrna-503 contributes to diabetes mellitus-induced impairment of endothelial function and reparative angiogenesis after limb ischemia. Circulation. 2011;123:282–291. This work demonstrates elevated plasma miR-503 levels in diabetic patients. In vitro, miR-503 is released from endothelial cells after exposure to high glucose, as model of hyperglycemia. PubMedCrossRef

77.

Carretero OA, Oparil S. Essential hypertension. Part i: Definition and etiology. Circulation. 2000;101:329–35.PubMedCrossRef

78.

Li S, Zhu J, Zhang W, Chen Y, Zhang K, Popescu LM, Ma X, Lau WB, Rong R, Yu X, Wang B, Li Y, Xiao C, Zhang M, Wang S, Yu L, Chen AF, Yang X, Cai J. Signature microrna expression profile of essential hypertension and its novel link to human cytomegalovirus infection. Circulation. 2011;124:175–84.PubMedCrossRef

79.

Cheng Y, Liu X, Yang J, Lin Y, Xu DZ, Lu Q, Deitch EA, Huo Y, Delphin ES, Zhang C. Microrna-145, a novel smooth muscle cell phenotypic marker and modulator, controls vascular neointimal lesion formation. Circ Res. 2009;105:158–66.PubMedCrossRef

80.

Wei J, Gao W, Zhu CJ, Liu YQ, Mei Z, Cheng T, Shu YQ. Identification of plasma microrna-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer. Chin J Cancer. 2011;30:407–14.PubMedCrossRef

81.

Kanemaru H, Fukushima S, Yamashita J, Honda N, Oyama R, Kakimoto A, Masuguchi S, Ishihara T, Inoue Y, Jinnin M, Ihn H. The circulating microrna-221 level in patients with malignant melanoma as a new tumor marker. J Dermatol Sci. 2011;61:187–93.PubMedCrossRef

82.

Wang K, Zhang S, Marzolf B, Troisch P, Brightman A, Hu Z, Hood LE, Galas DJ. Circulating micrornas, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci U S A. 2009;106:4402–7.PubMedCrossRef

83.

Qi R, Weiland M, Gao XX, Zhou L, Mi QS. Identification of endogenous normalizers for serum mirnas by microarray profiling: U6 snrna is not a reliable normalizer. Hepatology. 2011;doi:10.1002/hep.25558

84.

Lebanony D, Benjamin H, Gilad S, Ezagouri M, Dov A, Ashkenazi K, Gefen N, Izraeli S, Rechavi G, Pass H, Nonaka D, Li J, Spector Y, Rosenfeld N, Chajut A, Cohen D, Aharonov R, Mansukhani M. Diagnostic assay based on hsa-mir-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. J Clin Oncol. 2009;27:2030–7.PubMedCrossRef

85.

Szafranska-Schwarzbach AE, Adai AT, Lee LS, Conwell DL, Andruss BF. Development of a mirna-based diagnostic assay for pancreatic ductal adenocarcinoma. Expert Rev Mol Diagn. 2011;11:249–57.PubMed

86.

Bianchi F, Nicassio F, Marzi M, Belloni E, Dallolio V, Bernard L, Pelosi G, Maisonneuve P, Veronesi G, Di Fiore PP. A serum circulating mirna diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer. EMBO Mol Med. 2011;3:495–503.PubMedCrossRef

Title: Circulating miRNAs: Reflecting or Affecting Cardiovascular Disease?
Authors: Vanessa P. M. van Empel
Leon J. De Windt
Paula A. da Costa Martins
Publication date: 01-12-2012
Publisher: Current Science Inc.
Published in: Current Hypertension Reports / Issue 6/2012
Print ISSN: 1522-6417
Electronic ISSN: 1534-3111
DOI: https://doi.org/10.1007/s11906-012-0310-7

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2012

The Ubiquitous Mineralocorticoid Receptor: Clinical Implications

Mechanisms of Lipotoxicity in the Cardiovascular System

Mechanisms and Consequences of Inflammatory Signaling in the Myocardium

Non-Communicable Disease: A Welcome and Long Needed Addition to the WHO’s 2012 World Heath Statistics

What Is the Optimal First-Line Agent in Children Requiring Antihypertensive Medication?

Heart Rate and Blood Pressure: Any Possible Implications for Management of Hypertension?

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage